Streetbeat News

Products Services

MBRX

Moleculin Biotech, Inc. (MBRX) reported additional preliminary interim data from its AML clinical trial, showing promising results in subjects with poor prognosis cytogenetics and/or mutations. The trial demonstrated a median durability of response of 6 months and increasing, with significant survival rates and no cardiotoxicity. The data was presented at the European Hematology Association 2024 Hybrid Congress.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:05 pm

JSPR

Jasper Therapeutics presented preclinical data on Briquilimab at the 2024 EHA Hybrid Congress, showcasing promising results.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:04 pm

JNJ

Johnson & Johnson has reported long-term data from its Phase 1/2 Monumental-1 study, which could have significant implications for the company's future product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:04 pm

TAK

Takeda has signed an option agreement with Ascentage Pharma for the exclusive license of Olverembatinib, a potential third-generation BCR-ABL TKI for CML and other hematological cancers. The license excludes Mainland China, Hong Kong, Macau, Taiwan, and Russia. Takeda will receive the exclusive option to license global rights to Olverembatinib in all other territories. Ascentage Pharma will advance late-stage clinical development of Olverembatinib before Takeda potentially exercises the option.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:02 pm

MOLN

Molecular Partners shares are trading higher after the company announced preclinical proof-of-concept data from MP0621.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:00 pm

BPTH

Bio-Path Holdings shares are trading higher following the announcement of positive interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:54 am

TSLA

Tesla Inc. (NASDAQ:TSLA) will recall nearly 6,000 imported vehicles in China due to faulty seat belt warnings. The recall involves Model 3, S, and X vehicles and will be addressed via an over-the-air software update. This follows a similar recall in the U.S. affecting over 125,000 vehicles.

Portfolio Pulse from Anan Ashraf

June 14, 2024 | 11:51 am

RBLX

VDC

WMT

XLP

Walmart Inc (NYSE:WMT) is relaunching its 'No Boundaries' fashion line to attract Gen Z customers, with a focus on modern design and affordability. The collection will launch on July 16th and feature 130 new items, including eco-friendly innovations. Walmart has also partnered with Roblox Corp (NYSE:RBLX) to offer virtual outfits. Walmart stock has gained over 27% in the last 12 months.

Portfolio Pulse from Shivani Kumaresan

June 14, 2024 | 11:50 am

ADBE

GME

MSM

QQQ

SPY

TSLA

US stocks are expected to end the week on a subdued note after a record run, with major index futures moderately lower. Adobe Inc. (ADBE) is set to boost the tech sector, while GameStop Corp. (GME) and MSC Industrial Direct Co., Inc. (MSM) are experiencing declines. The SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) show mixed premarket performance. Key economic data and Federal Reserve speeches are anticipated to influence market movements.

Portfolio Pulse from Shanthi Rexaline

June 14, 2024 | 11:45 am

TSLA

Tesla Inc (NASDAQ:TSLA) is ramping up production of its Cybertruck, aiming to reach 2,500 units per week by the end of the year. Currently, the production rate is at 1,300 units per week. The company plans to eventually deliver 250,000 Cybertrucks annually starting in 2025. The Cybertruck is currently limited to the U.S. market, with potential international availability next year. Tesla will soon stop producing the foundation series and start shipping non-foundation series Cybertrucks next quarter.

Portfolio Pulse from Anan Ashraf

June 14, 2024 | 11:41 am